Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy

被引：15

作者：

Aparo, Santiago ^{[1
]}

Goel, Sanjay ^{[1
]}

机构：

[1] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med Oncol, Bronx, NY 10467 USA

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2012年 / 83卷 / 01期

基金：

美国国家卫生研究院;

关键词：

Colorectal neoplasms; Neoplasm metastasis; Therapy; ADVANCED COLORECTAL-CANCER; PHASE-III TRIAL; CETUXIMAB PLUS IRINOTECAN; RANDOMIZED CONTROLLED-TRIAL; GROWTH-FACTOR RECEPTOR; 1ST-LINE TREATMENT; CONTINUOUS-INFUSION; HEPATIC METASTASES; SURGICAL RESECTION; LIVER METASTASES;

D O I：

10.1016/j.critrevonc.2011.08.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Colorectal Cancer is the second most common cancer in incidence and mortality in the United States. In spite of current screening strategies 1 out of 5 patients still presents with metastatic disease. During the last 10-15 years there has been significant increase in the availability of chemotherapy options for this disease. The recent introduction of molecular markers to the treatment algorithm allows oncologists to tailor treatments for each particular patient. In the following article we give an overview of the landmark publications that led to our current standards and we give our view on particular situations in which the available evidence is not so helpful in making therapeutic decisions. (C) 2011 Elsevier Ireland Ltd. All rights reserved.

引用

页码：47 / 58

页数：12

共 58 条

[41] Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial [J].

Nordlinger, Bernard ;

Sorbye, Halfdan ;

Glimelius, Bengt ;

Poston, Graeme J. ;

Schlag, Peter M. ;

Rougier, Philippe ;

Bechstein, Wolf O. ;

Primrose, John N. ;

Euan, T. Walpole ;

Finch-Jones, Meg ;

Jaeck, Daniel ;

Mirza, Darius ;

Parks, Rowan W. ;

Collette, Laurence ;

Praet, Michel ;

Bethe, Ullrich ;

Van Cutsem, Eric ;

Scheithauer, Werner ;

Gruenberger, Thomas .

LANCET, 2008, 371 (9617) :1007-1016

[42] Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer [J].

Peeters, Marc ;

Price, Timothy Jay ;

Cervantes, Andres ;

Sobrero, Alberto F. ;

Ducreux, Michel ;

Hotko, Yevhen ;

Andre, Thierry ;

Chan, Emily ;

Lordick, Florian ;

Punt, Cornelis J. A. ;

Strickland, Andrew H. ;

Wilson, Gregory ;

Ciuleanu, Tudor-Eliade ;

Roman, Laslo ;

Van Cutsem, Eric ;

Tzekova, Valentina ;

Collins, Simon ;

Oliner, Kelly S. ;

Rong, Alan ;

Gansert, Jennifer .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) :4706-4713

[43] Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated meta-analysis [J].

Piedbois, P .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) :3766-3775

[44] Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO colorectal study group [J].

Porschen, Rainer ;

Arkenau, Hendrik-Tobias ;

Kubicka, Stephan ;

Greil, Richard ;

Seufferlein, Thomas ;

Freier, Werner ;

Kretzschmar, Albrecht ;

Graeven, Ullrich ;

Grothey, Axel ;

Hinke, Axel ;

Schmiegel, Wolff ;

Schmoll, Hans-Joachim .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (27) :4217-4223

[45]

Prevett MC, 2002, CLIN CANCER RES, V8, P994

[46] Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial [J].

Rothenberg, ML ;

Oza, AM ;

Bigelow, RH ;

Berlin, JD ;

Marshall, JL ;

Ramanathan, RK ;

Hart, LL ;

Gupta, S ;

Garay, CA ;

Burger, BG ;

Le Bail, N ;

Haller, DG .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (11) :2059-2069

[47] Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. [J].

Saltz, LB ;

Cox, JV ;

Blanke, C ;

Rosen, LS ;

Fehrenbacher, L ;

Moore, MJ ;

Maroun, JA ;

Ackland, SP ;

Locker, PK ;

Pirotta, N ;

Elfring, GL ;

Miller, LL .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (13) :905-914

[48] Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study [J].

Saltz, Leonard B. ;

Clarke, Stephen ;

Diaz-Rubio, Eduardo ;

Scheithauer, Werner ;

Figer, Arie ;

Wong, Ralph ;

Koski, Sheryl ;

Lichinitser, Mikhail ;

Yang, Tsai-Shen ;

Rivera, Fernando ;

Couture, Felix ;

Sirzen, Florin ;

Cassidy, Jim .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) :2013-2019

[49] EPIC:: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer [J].

Sobrero, Alberto F. ;

Maurel, Joan ;

Fehrenbacher, Louis ;

Scheithauer, Werner ;

Abubakr, Yousif A. ;

Lutz, Manfred P. ;

Vega-Villegas, M. Eugenia ;

Eng, Cathy ;

Steinhauer, Ernst U. ;

Prausova, Jana ;

Lenz, Heinz-Josef ;

Borg, Christophe ;

Middleton, Gary ;

Kroening, Hendrik ;

Luppi, Gabriele ;

Kisker, Oliver ;

Zubel, Angela ;

Langer, Christiane ;

Kopit, Justin ;

Burris, Howard A., III .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (14) :2311-2319

[50] OPTIMOX1:: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer -: A GERCOR study [J].

Tournigand, C ;

Cervantes, A ;

Figer, A ;

Lledo, G ;

Flesch, M ;

Buyse, M ;

Mineur, L ;

Carola, E ;

Etienne, PL ;

Rivera, F ;

Chirivella, I ;

Perez-Staub, N ;

Louvet, C ;

André, T ;

Tabah-Fisch, I ;

de Gramont, A .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) :394-400

← 1 2 3 4 5 6 →